bioRxivGeneticsPreprint
Discovery of novel putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in AML cells
W. Frank LenoiriD, Micaela Morgado, Peter C DeWeirdt, Megan McLaughlin, Audrey L GriffithiD, Annabel K Sangree, Marissa N Feeley, Nazanin Esmaeili AnvariD, Eiru KimiD, Lori L Bertolet, Medina ColiciD, Merve DedeiD, John G. DoenchiD, Traver HartiD
Abstract
CRISPR knockout screens in hundreds of cancer cell lines have revealed a substantial number of context-specific essential genes that, when associated with a biomarker such as lineage or oncogenic mutation, offer candidate tumor-specific vulnerabilities for targeted therapies or novel drug development. Data-driven analysis of knockout fitness screens also yields many other functionally coherent modules that show emergent essentiality or, in rarer cases, the opposite phenotype of faster proliferation. We develop a systematic approach to classify these suppressors of proliferation, which are highly enriched for tumor suppressor genes, and define a network of 145 genes in 22 discrete modules. One surprising module contains several elements of the glycerolipid biosynthesis pathway and operates exclusively in a subset of AML lines, which we call Fatty Acid Synthesis/Tumor Suppressor (FASTS) cells. The proliferation suppressor activity of genes involved in the synthesis of saturated fatty acids, coupled with a more severe fitness phenotype for the desaturation pathway, suggests that these cells operate at the limit of their carrying capacity for saturated fatty acids, which we confirmed biochemically. Overexpression of genes in this module is associated with a survival advantage in an age-matched cohort of AML patients, suggesting the gene cluster driving an in vitro phenotype may be associated with a novel, clinically relevant subtype.
- organism: human
- assay: CRISPR screen
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome-wide CRISPR Screens Identify Ferroptosis as a Novel Therapeutic Vulnerability in Acute Lymphoblastic Leukemia
M.-E. Lalonde, M. Sasseville, … R. Marcotte·bioRxiv·Feb 1, 2022
- An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML
S. Lin, C. Larrue, … K. Stegmaier·bioRxiv·Dec 28, 2020
- CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer drivers
Jessica Desjardins, Julian Bowlan, … Jordan T.F. Young·bioRxiv·Jan 25, 2026
- An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs
A. L. Cook, N. Wyhs, … K. W. Kinzler·bioRxiv·Aug 6, 2021
- Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
J. M. Krill-Burger, J. M. Dempster, … A. Tsherniak·bioRxiv·Mar 2, 2022
- CRISPR screens in physiologic medium reveal conditionally essential genes in human cells
N. J. Rossiter, K. S. Huggler, … J. R. Cantor·bioRxiv·Aug 31, 2020